You need a reliable and responsive partner in your CRO – one that has the skills and flexibility to manage your challenging requirements and timelines. That means you are looking for a track record of quality and commitment. Envigo has more than 30 years of experience in carcinogenicity studies. We have carried out more than 500 studies in the last 10 years alone. As our drug development customer, you enjoy full access to our substantial scientific and technical resources and expertise to deliver high quality, regulatory-compliant carcinogenicity studies when you need them, how you need them.

Expand All Tabs
  • Individually ventilated cages option
  • Oral, dietary, inhalation, dermal and subcutaneous routes
  • Preliminary study development
  • Mode of action’ analysis
  • Pathology
  • Statistical analysis
  • Regulatory advice
  • Short term mouse models, Tg.rasH2 and P53+/-

Envigo’s carcinogenicity group is led by our team of senior scientists who together have more than 150 years combined experience. They are supported by a dedicated pathology department (MRCPath qualified), as well as expert statistical analysts, study directors and technicians, and many experts in the management of fast-track studies.

The future of inhaled medications and inhalation technology

[Webinar] De-risking drug development: in vitro strategies that add value to your molecule